Palantir stock hits 52-week low after seventh straight drop

Palantir Technologies shares fell 5.8% to $106.88 on Thursday, marking a seventh consecutive session of losses and a 52-week low. The stock has slipped nearly 20% since last Tuesday and is down about 31% for the month. If the decline persists through month-end, it would be the company’s worst monthly drop since February 2021, when shares fell 32%.

Year to date, Palantir shares have declined roughly 39% and stand about 48% below their record closing high of $207.18 on Nov. 3, 2025. By comparison, the S&P 500 has gained 7.8% this year and the Nasdaq Composite is up 9%.

Technical indicators have deteriorated in recent days. On Monday the stock moved below a support level near $127 that had been in place since February and is trading roughly 15% under that level. Thursday’s trading pushed the price below a weekly support area that had held for about a year. The share price is below its major moving averages, with the 50-day average near $137 and the 200-day average around $159.

Valuation metrics are also a factor. Palantir’s trailing price-to-earnings ratio is above 100, a level that leaves the stock exposed if investors re-price high-multiple software companies amid shifting interest-rate expectations and weakness in semiconductor and hardware sectors.

Separately, international contract developments have added pressure. France’s domestic intelligence agency announced plans to phase out Palantir tools in favor of a domestically developed alternative from ChapsVision. In the U.K., parliamentary committees have increased scrutiny of Palantir’s Federated Data Platform contract with the National Health Service and have urged the government to consider exercising a February 2027 break clause that could end the agreement.

Some analysts remain optimistic on Palantir’s long-term prospects. Wolfe Research resumed coverage with an upgraded rating and its analyst Alex Zukin wrote that the firm views Palantir as a leading applied enterprise AI software company and described the business as attractive under an upside growth scenario. Data from FactSet shows an average analyst rating of Overweight and a consensus price target of $189.87, implying roughly 67% upside from current levels. Of 33 firms covering the stock, FactSet lists 17 Buy ratings, three Overweight, 11 Hold and two Sell.

Market participants are watching share-price action, technical levels and developments on international contracts as the company approaches the end of the month.